Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross SC specialty drug Prior Auth Policy Upd…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Specialty drug prior authorization and medical necessity criteria (immunology/rheumatology and other specialties)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, prior authorization requirements, clinical criteria, prescriber restrictions, age limits, coverage durations, and prerequisite therapy policies for multiple specialty medications on the Blue Cross Blue Shield - South Carolina formulary; affects providers requesting coverage for listed products.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicySpecialty drug prior authorization and medical necessity criteria (immunology/rheumatology and other specialties)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with indication-specific documentation including diagnosis, required prior therapy trials or contraindications, and prescriber specialty when specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multiple (≥15)products listed in this excerpt
    12 motypical coverage duration
    6 moinitial durations noted
    26218formulary identifier

    Coverage criteria by product / indication

    This section defines the specific coverage criteria that must be met for the products listed in this document. For each product, coverage is limited to the labeled, indication‑specific clinical scenarios and requires submission of the required medical information described in the criteria (for example: diagnosis confirmation, relevant laboratory or genetic test results, prior therapy trial documentation, and prescriber specialty or consultation when specified) and is subject to coverage durations noted per product (commonly 12 months for many agents). (See individual product entries for per‑indication thresholds such as ≥10% BSA for certain atopic dermatitis indications and other age or laboratory cutoffs.)

    Some product entries explicitly list that off‑label uses = N/A, indicating no off‑label coverage criteria are provided in this excerpt; where off‑label use is not permitted, that exclusion is noted in the product entry. Prior authorization is required for products in this section and documentation must demonstrate the indication‑specific criteria and any prerequisite therapy trials or contraindication/intolerance attestations as applicable.

    Several individual product entries in this excerpt explicitly state Off‑Label Uses = N/A, meaning the policy does not provide approval criteria for off‑label indications for those products. Examples in these chunks include specialty biologic and small‑molecule product listings where off‑label criteria are not provided and exclusions are summarized alongside the required indication documentation.

    When off‑label use is not addressed (noted as N/A) or when a product has explicit exclusions (for example, certain combination uses or specific disease contexts), the request will be evaluated only against the listed, on‑label criteria and documented prerequisites (diagnosis confirmation, required prior therapy trials, laboratory or genetic testing, prescriber specialty/consultation). Absent the required on‑label documentation, requests risk denial per the product‑specific prior authorization rules.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicySpecialty drug prior authorization and medical necessity criteria (immunology/rheumatology and other specialties)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with indication-specific documentation including diagnosis, required prior therapy trials or contraindications, and prescriber specialty when specified.
    SourceLink
    On This Page
    Coverage criteria by product / indicationPrior authorization, step therapy, and documentation requirementsFormulary identifiers, codes, and clinical thresholdsKey definitions and clinical terms used in criteriaPolicy background and scope summaryPolicy revision history

    Prior authorization, step therapy, and documentation requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required for initiation and reauthorization of listed specialty medications; submit indication-specific documentation including diagnosis, prior therapy trials (TF/C/I) at maximally tolerated doses where specified, prescriber specialty or consultation when required, and evidence of positive clinical response for reauthorization.

    • Submit documentation of diagnosis and relevant test results per drug-specific criteria.
    • Document prior trial and failure, contraindication, or intolerance to required conventional therapies where listed (TF/C/I).
    • Include prescriber specialty or consultation notes when indicated (e.g., rheumatology, neurology, pulmonology).
    Prior Authorization

    Dalfampridine ER prior auth

    For dalfampridine ER initial requests, the drug must be prescribed by or in consultation with a neurologist and the request must include physician confirmation of difficulty walking (e.g., timed 25-foot walk) plus either EDSS ≤ 7 or documentation the patient is not wheelchair-restricted.

    • Initial approval duration: 6 months; reauthorization requires physician confirmation of improved walking and is 12 months.
    • Include neurologist prescriber or consultation note and objective walking assessment.
    Prior Authorization

    Benlysta prior auth

    Benlysta (IV/SC) initial and reauthorization requests must be prescribed by or in consultation with a rheumatologist (or nephrologist for lupus nephritis) and include documentation of active disease, positive autoantibody (ANA ≥1:80 or anti-dsDNA ≥30 IU/mL), and concurrent standard of care therapy.

    • Coverage duration: initial and reauth 6 months; reauth requires demonstration of positive clinical response.
    • Provide rheumatology (or nephrology) consult notes and relevant serology results (ANA, anti-dsDNA).
    Prior Authorization

    Arikayce prior auth

    Arikayce prior authorization must document Mycobacterium avium complex (MAC) lung disease, use as part of a multidrug antibacterial regimen, and that the patient did not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of multidrug background therapy; prescribed by or in consultation with an infectious disease specialist or pulmonologist.

    • Coverage duration: 12 months.
    • Include sputum culture history showing fewer than two negative cultures after ≥6 months of background therapy and specialist documentation.
    Prior Authorization

    Prior authorization required per product

    Many products require prior authorization with documentation that the member tried and failed, or had contraindication/intolerance to, specified alternative or conventional therapies (TF/C/I) at required minimum durations before biologic or specialty agent initiation.

    • Step therapy/TF/C/I must be documented at maximally tolerated doses where specified.
    • Specify duration of prior trials when listed (e.g., 3 months for RA conventional therapy).
    Prior Authorization

    Prior authorization required for listed products

    Prior authorization applies to certain listed products for muscle spasm and related uses; for patients age ≥65 PA applies and prescribers must acknowledge anticholinergic risks; some entries require use of a prerequisite Part D drug.

    • PA applies to patients ≥65 years for muscle spasm indications.
    • Prescriber must acknowledge anticholinergic risks and consider dose reduction or discontinuation of other anticholinergic medications.
    Prior Authorization

    Dupixent PA requirements

    Dupixent requests require prior authorization with indication-specific documentation: document the diagnosis, relevant eosinophil thresholds (e.g., ≥150 cells/µL baseline for some asthma indications or ≥300 cells/µL for COPD), age- and therapy-specific controller medication trials, and specialist prescribing/consultation when indicated.

    • Include baseline peripheral blood eosinophil count and prior controller therapy details.
    • Prescriber should be pulmonologist or allergist/immunologist for asthma indications.
    Prior Authorization

    Empaveli PA requirements

    Empaveli prior authorization requires documentation of the specific diagnosis (PNH or C3G/primary IC‑MPGN) and, for C3G/IC‑MPGN, evidence the patient has been treated with a maximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor for at least 12 weeks to reduce proteinuria; prescriber specialty (hematology or nephrology) must be documented.

    • Coverage duration: 12 months; reauth requires positive clinical response.
    • Provide documentation of 12-week maximally tolerated ACEi/ARB or SGLT2 trial where applicable and specialist consult notes.
    Prior Authorization

    Prior authorization required for listed specialty drugs

    Many specialty drugs in this formulary section require prior authorization consistent with the listed required medical information, including diagnosis confirmation, prior therapy trials, prescriber restrictions, and supporting test results; follow the product‑specific submission requirements.

    • Include specific supporting documents per product (e.g., genetic testing, pathology, lab thresholds).
    • Document prescriber specialty or consultation when specified.
    Prior Authorization

    Enbrel prior auth requirements

    Enbrel and its formulations require prior authorization with documentation of indication‑specific prior therapy trials and minimum durations (e.g., 3 months TF/C/I to conventional therapy for RA; 6 weeks for PJIA; 1 month NSAID trial for AS) and prescriber specialty consultation where listed.

    • Initial duration typically 6 months; reauthorization 12 months with demonstrated positive clinical response.
    • Provide documentation of trials at maximally tolerated doses (e.g., methotrexate for RA).
    Prior Authorization

    Prior authorization required

    Prior authorization is required with submission of drug-specific supporting documentation including diagnosis, prior therapies, relevant labs or test results, and prescriber specialty/consultation as specified for each medication.

    • Reauthorization generally requires demonstration of positive clinical response per indication.
    • Follow the product entry for exact documentation and duration requirements.
    Prior Authorization

    Prior authorization required

    Prior authorization requests must include documentation of diagnosis, prior therapy trials or documented contraindications/intolerance, and prescriber specialty or consultation notes when required by the product criteria.

    • For reauthorization, include objective evidence of positive clinical response compared to baseline as defined per indication.
    • Ensure prior trials meet required minimum durations and were at maximally tolerated doses when specified.
    Prior Authorization

    Product-specific prior authorization required

    Product-specific prior authorization is required per the criteria: include diagnosis confirmation, prerequisite therapy trials or contraindications, prescriber specialty requirements, and documented clinical response for reauthorization (most approvals are 12 months).

    • Check each product entry for prerequisite Part D drug requirements and duration.
    • Include molecular/genetic test results when required by the product.
    Prior Authorization

    Kesimpta prior authorization

    Kesimpta prior authorization requires documentation of a relapsing form of MS, either trial and failure (minimum 4‑week supply), contraindication/intolerance to one disease‑modifying therapy or documentation of continuation of prior therapy, and prescriber is neurologist or neurologist consult; Kesimpta must not be used in combination with another DMT or other B‑cell targeted therapy.

    • Coverage duration: 12 months; reauth requires demonstration of positive clinical response.
    • Do not submit requests showing concurrent use with other DMTs or B‑cell targeted therapies.
    Prior Authorization

    Kineret prior authorization

    Kineret prior authorization requires documentation of diagnosis (e.g., moderately to severely active RA or confirmed NOMID), and for RA initial therapy documentation of trial and failure (or contraindication/intolerance) to two listed agents unless attestation justifies omission; prescriber specialty must be documented.

    • Initial coverage for RA/NOMID often 6 months; reauth 12 months and requires evidence of positive clinical response.
    • Provide rheumatologist consult notes and records of prior agent trials and durations.
    Documentation Required

    Prior authorization required with condition-specific documentation

    Prior authorization requests must include diagnosis‑specific documentation, relevant test results (e.g., genetic/molecular testing, labs, imaging), prescriber specialty/consultation notes when required, and prior therapy history as specified by the product.

    • Provide FDA‑ or CLIA‑approved test results when molecular testing is required.
    • Include baseline disease measures cited by the product (e.g., BSA, CDAI, eosinophil counts).
    Prior Authorization

    Prior authorization required

    Prior authorization is required with product‑specific clinical criteria — submit diagnosis confirmation, prior therapy trials or contraindication/intolerance documentation, prescriber specialty notes when specified, and note that many approvals default to 12 months.

    • Follow each product entry for exact lab thresholds, imaging, or biopsy requirements.
    • Include specialist consultation notes where the policy requires a specialist prescriber.
    Prior Authorization

    Onureg prior authorization

    Onureg prior authorization requires documentation of AML diagnosis, prior intensive induction chemotherapy, achievement of CR or CRi, and that the patient is unable to complete intensive curative therapy; include required Part D prerequisite drug documentation.

    • Coverage duration: 12 months; approve continuation of prior therapy.
    • Submit detailed chemotherapy history and documentation of remission status (CR/CRi).
    Prior Authorization

    Orencia prior authorization

    Orencia prior authorization for RA, PJIA, and PsA initial approvals requires diagnosis and documentation of trial and failure/intolerance to specified conventional therapies (e.g., methotrexate, leflunomide, sulfasalazine) with initial duration 6 months and reauth 12 months; reauthorization requires demonstration of positive clinical response.

    • Provide rheumatology consult notes and records of prior conventional therapy trials at maximally tolerated doses.
    • Ensure prerequisite Part D drug documentation is included when required.
    Prior Authorization

    PAH agents prior authorization

    PAH agents (Opsumit, Orenitram, Orenitram titration kits) require prior authorization with confirmation of symptomatic PAH by right heart catheterization or documentation that the patient is currently on PAH therapy; initial approvals are typically 6 months with reauthorizations at 12 months and specialist prescriber involvement (pulmonologist or cardiologist) for initiation.

    • Submit right heart catheterization report when available or document current PAH therapy.
    • Include pulmonology or cardiology consult notes for initial therapy.
    Prior Authorization

    Ozempic prior authorization

    Ozempic prior authorization requires documentation for the intended indication: for T2DM submit diagnostic records or labs (A1c ≥6.5%, FPG ≥126 mg/dL, or 2‑hr OGTT ≥200 mg/dL); for MASH submit diagnostic confirmation and fibrosis staging (FAST, MAST, or liver biopsy) and specialist consult when indicated.

    • Coverage duration: 12 months; reauth requires positive clinical response.
    • Include fibrosis stage (F2–F3) documentation for MASH and endocrinology/hepatology/gastroenterology consult notes as applicable.
    Prior Authorization

    Prior authorization requirement

    Prior authorization is required generally with submission of indication‑specific documentation and evidence of prerequisite therapies or test results per the product entry; include prescriber specialty information where mandated.

    • Check each product for prerequisite Part D drug requirements and include supporting lab/imaging/genetic results.
    • For reauthorization, document improvement from baseline using the disease‑specific measures cited.
    Prior Authorization

    Prior authorization required

    Prior authorization requires documentation of diagnosis-specific criteria (diagnosis, prior therapy trials, baseline disease measures) for initiation and reauthorization; follow the product entries for exact required measures and trial durations.

    • Provide baseline disease measures (e.g., BSA, CDAI, eosinophil counts) and prior therapy histories including durations.
    • Include prescriber specialty notes when required (e.g., dermatologist, gastroenterologist, rheumatologist).
    Prior Authorization

    Prior authorization required for specialty indications

    For specialty indications, prior authorization requires documentation of diagnosis and prior therapy trials as specified (for example PJIA requires a minimum 6‑week TF/C/I to methotrexate or leflunomide and documentation of TNF inhibitor failure/intolerance where applicable).

    • Initial coverage commonly 6 months with reauth 12 months and reauth requires demonstration of positive clinical response.
    • Include rheumatology consultation notes and records of TNF inhibitor trials when applicable.
    Step Therapy

    Step therapy requirements

    Many products require step therapy: document trial and failure, contraindication, or intolerance (TF/C/I) to specified conventional or topical therapies at maximally tolerated doses before approval of biologic or specialty agents.

    • Confirm the required number and classes of prior agents (e.g., one conventional DMARD for RA, two agents for some Kineret indications).
    • Document trial durations and reasons for failure, contraindication, or intolerance.
    Step Therapy

    Caplyta step therapy

    Caplyta step therapy requires documentation of trial and failure, contraindication, or intolerance to specified oral generic atypical antipsychotics depending on the indication (e.g., two agents required for certain MDD adjunctive uses).

    • Provide documentation of trials of listed atypical antipsychotics and reason for failure or intolerance.
    • Include prior Part D drug records when indicated.
    Step Therapy

    Step therapy / TF/C/I requirements

    Many products require step therapy (TF/C/I) of specified formulary alternatives—examples include oral atypical antipsychotics for Caplyta and topical or NSAID trials for dermatologic or rheumatologic biologics—document the trials, durations, and outcomes.

    • Ensure documentation shows trials at maximally tolerated doses and minimum durations where specified (e.g., 30 days topical trial for psoriasis).
    • If a prerequisite Part D drug is required, include that evidence.
    Documentation Required

    Deferasirox — laboratory and transfusion prerequisites

    Deferasirox initial and reauthorization criteria require laboratory thresholds and transfusion history: initial ferritin >1000 mcg/L and transfusion of ≥100 mL/kg packed RBCs for transfusional iron overload; NTDT requires LIC ≥5 mg Fe/g dw and ferritin >300 mcg/L; reauth requires reduction in ferritin or LIC.

    • Include baseline ferritin and transfusion history or LIC by MRI when applicable.
    • Reauthorization must show reduction from baseline in serum ferritin or LIC.
    Step Therapy

    Enbrel step therapy

    Enbrel step therapy requires documentation of prior trials of conventional systemic therapies or topical agents as specified per indication before initiation of Enbrel (e.g., 3 months TF/C/I to conventional therapy for RA; 6‑week trial for PJIA; topical trial for plaque psoriasis).

    • Provide documentation of trial durations and outcomes at maximally tolerated doses.
    • Include rheumatology or dermatology consult notes when applicable.
    Step Therapy

    Prerequisite therapy variability

    Prerequisite therapy requirements vary by product; some agents (e.g., Fasenra, Cosentyx) require use of a prerequisite Part D drug or documented escalation of controller therapy, while others do not—always follow the specific product entry.

    • Check the product entry for whether a prerequisite Part D drug is required and document accordingly.
    • Include controller therapy details and escalation attempts where relevant.
    Step Therapy

    Step therapy / required prior medications

    Many inflammatory and autoimmune agents require documented trial and failure, contraindication, or intolerance (TF/C/I) to specified conventional therapies (e.g., methotrexate, leflunomide, sulfasalazine for RA; NSAID trial for AS; topical therapy trial for plaque psoriasis) before biologic initiation.

    • Document trials at maximally tolerated doses and record reasons for discontinuation or failure.
    • Provide prescriber specialty notes (rheumatologist, dermatologist, gastroenterologist) as required.
    Step Therapy

    Prerequisite trial requirements

    Many products require documented TF/C/I to specified prior therapies (e.g., Kesimpta requires TF/C/I to one DMT; Kineret RA initial requires TF/C/I to two specified agents); submit records of prior agents tried and reasons for failure/intolerance.

    • Include dates, doses, and duration of prior therapy trials (minimum durations where specified).
    • If attestation is used to exempt a trial, include justification and supporting documentation.
    Step Therapy

    Kineret step therapy requirement

    Kineret for RA initial therapy requires documentation of trial and failure, contraindication, or intolerance to two listed agents (examples include etanercept, a formulary adalimumab product, abatacept, upadacitinib, tofacitinib) unless an attestation justifies omission.

    • Provide documentation of the two prior agent trials or an attestation explaining why trials are inappropriate.
    • Prescriber should be a rheumatologist or consult with one for initial requests.
    Step Therapy

    Required trial and failure of specified agents

    Some products require trial and failure of specified agents before approval (examples: trial of a triptan before dihydroergotamine for acute migraine); document the specific agent trials and outcomes.

    • Include evidence of triptan trial and reason for failure or contraindication when required.
    • Follow product-specific minimum durations for prior agent trials.
    Step Therapy

    Step therapy / trial requirements

    Many products require trial and failure or contraindication/intolerance to specific alternative agents (e.g., schizophrenia therapies before Opipza; intranasal corticosteroid and antihistamine before Odactra; fludrocortisone or midodrine before droxidopa); document prior agent trials and specialist consults as indicated.

    • For Opipza, document trials of two specified antipsychotics and reasons for failure/intolerance.
    • For Odactra, include positive specific IgE or skin testing and documentation of prior intranasal corticosteroid and antihistamine trial.
    Step Therapy

    Opipza step therapy

    Opipza (antipsychotic) requires trial and failure, contraindication, or intolerance to two specified antipsychotics for schizophrenia and other indicated diagnoses; include records of those trials.

    • Document dates, doses, and reasons for discontinuation of the two prior antipsychotic trials.
    • Include psychiatric specialist notes when available.
    Step Therapy

    Step therapy requirements

    Step therapy is required for multiple agents (e.g., Infliximab requires documented TF/C/I to specified conventional therapies; PCSK9 inhibitors require maximal tolerated statin/ezetimibe or documented statin intolerance); include prior therapy history and lipid/response labs where applicable.

    • For PCSK9 inhibitors, include LDL‑C results and documentation of maximally tolerated statin or statin intolerance.
    • For infliximab, provide records of conventional therapy trials and CDAI or other disease activity measures as applicable.
    Step Therapy

    Step therapy / TNF inhibitor prerequisite

    Many inflammatory indications require prior trial and failure, contraindication, or intolerance to specified conventional therapies and often at least one TNF inhibitor before approval of certain agents (e.g., Rinvoq/Rinvoq LQ, other advanced biologics); document prior TNF inhibitor use and outcomes.

    • Include TNF inhibitor trial dates, doses, reasons for discontinuation, and prescriber specialty notes.
    • Reauthorization requires demonstration of positive clinical response from baseline.
    Step Therapy

    Step therapy / prerequisite trials

    Several products require documented trial and failure or contraindication to specified topical, conventional, or biologic therapies before approval (e.g., topical therapy trials for plaque psoriasis, conventional DMARDs for PJIA); provide documentation of those prior trials and outcomes.

    • For plaque psoriasis, document topical therapy trials (minimum 30 days; 14 days for topical corticosteroids) and BSA measurements.
    • For PJIA, include 6‑week trial documentation of methotrexate or leflunomide.
    Documentation Required

    Required clinical and prior therapy documentation

    Providers must document diagnosis, prior trial and failure/contraindication/intolerance to required conventional therapies where specified, evidence of disease activity per indication (e.g., BSA for psoriasis, CDAI for Crohn's), and for reauthorization document positive clinical response compared to baseline.

    • Include objective baseline and follow‑up measures (e.g., joint counts, BSA, CDAI, lab markers).
    • Attach prescriber specialty consultation notes when required by the product criteria.
    Documentation Required

    Augtyro required diagnostic and prior therapy info

    Augtyro prior authorization requires documentation of tumor ROS1 rearrangement for NSCLC or NTRK gene fusion for solid tumors, stage (locally advanced or metastatic), prior therapy history (progression after prior treatment or lack of satisfactory alternatives), and specialist prescriber notes.

    • Provide FDA‑ or CLIA‑approved molecular test results demonstrating ROS1 or NTRK fusion.
    • Include oncology consult notes and prior line therapy documentation.
    Documentation Required

    Balversa molecular and prior therapy documentation

    Balversa prior authorization requires documentation of locally advanced or metastatic urothelial carcinoma with a susceptible FGFR3 alteration detected by an FDA‑approved or CLIA test, prior systemic therapy history including PD‑1/PD‑L1 exposure or documented ineligibility, and specialist prescriber notes.

    • Submit FGFR3 test results from an FDA‑approved or CLIA‑certified laboratory.
    • Include prior systemic therapy records and oncology specialist documentation.
    Documentation Required

    Cabometyx required information

    Cabometyx prior authorization requires documentation of the specific diagnosis (RCC, HCC, DTC, neuroendocrine tumors), prior therapy trials (e.g., sorafenib or VEGFR‑targeted therapies) where applicable, and prescriber specialty notes.

    • Provide prior therapy details and dates showing treatment sequence per indication.
    • Include oncology specialist consultation notes.
    Documentation Required

    Diagnostic testing documentation

    For bile acid synthesis disorders or peroxisomal disorders, submit abnormal urinary bile acid analysis by mass spectrometry or molecular genetic testing consistent with the diagnosis and specialist prescriber documentation (hepatologist, geneticist, gastroenterologist, or inborn errors specialist).

    • Include laboratory mass spectrometry reports or genetic testing results.
    • Document specialist consultation and evidence of liver disease or fat‑soluble vitamin malabsorption where applicable.
    Documentation Required

    HAE diagnostic documentation

    For hereditary angioedema (HAE) prophylaxis and acute therapy, provide diagnostic testing documentation including C4 level and C1‑INH antigenic or functional level, or genetic testing/family history consistent with HAE‑nl‑C1INH as specified; prescriber should be an immunologist or allergist for many HAE entries.

    • Include C4 and C1‑INH results or genetic testing reports.
    • Document specialist prescriber involvement and history of HAE attacks when relevant.
    Documentation Required

    Anticholinergic risk acknowledgement

    When prescribing anticholinergic‑risk medications (e.g., cyclobenzaprine) prescribers must acknowledge anticholinergic risks and consider dose reduction or discontinuation of unnecessary medications, and note that PA applies for patients age ≥65 years.

    • Document the prescriber's anticholinergic risk acknowledgement in the medical record.
    • For patients ≥65, include justification for therapy and prior therapy trials where required.
    Documentation Required

    Metyrosine — diagnostic confirmation and prescriber consult

    For preoperative metyrosine, submit biochemical confirmation of pheochromocytoma (plasma free metanephrines or urinary fractionated metanephrines) and document specialist prescribing/consultation; trials of alpha and beta blockers may be required before therapy in many cases.

    • Provide plasma or urine metanephrine test results and endocrinology or surgical consult notes.
    • Document trials or contraindications to alpha‑ and beta‑adrenergic blockers as indicated.
    Documentation Required

    Required diagnostic and treatment history

    Provide diagnosis‑specific documentation as required by the product (e.g., PNH diagnosis for Empaveli; for C3G or primary IC‑MPGN include diagnosis, lack of prior transplant for primary IC‑MPGN, and evidence of at least 12 weeks of maximally tolerated ACEi/ARB or SGLT2 inhibitor therapy to reduce proteinuria).

    • Include nephrology or hematology consult notes and medication dose/history showing 12-week maximally tolerated therapy.
    • Attach laboratory or urine proteinuria measures supporting the diagnosis and treatment effect.
    Documentation Required

    Genetic and baseline motor function documentation

    For Evrysdi (SMA) prior authorization, submit genetic testing confirming SMN1 mutation/deletion and SMN2 copy number, baseline standardized motor exam results (e.g., HINE‑2, HFMSE, RULM, CHOP‑INTEND), and documentation regarding prior gene replacement therapy response if applicable.

    • If prior gene therapy was given, submit medical records documenting inadequate response (e.g., sustained decrease in motor test score over 6 months).
    • Include neurologist consult notes and baseline motor function assessments.
    Documentation Required

    Fabrazyme diagnostic documentation

    For Fabrazyme prior authorization, provide diagnostic confirmation of Fabry disease via pathogenic GLA mutation, deficient α‑Gal A enzyme activity, or significant clinical manifestations; include that Fabrazyme is not to be used in combination with other Fabry disease therapies.

    • Patient age ≥2 years; coverage 12 months with reauth requiring positive clinical response.
    • Attach genetic or enzyme assay results and specialist (neurology/cardiology/nephrology) consultation notes.
    Documentation Required

    Fasenra required clinical data

    For Fasenra and other eosinophil‑targeted therapies, include baseline peripheral blood eosinophil count (e.g., ≥150 cells/µL baseline for some asthma indications, ≥300 cells/µL for COPD), documentation of prior exacerbations or hospitalizations, and current controller therapy details appropriate for the patient's age.

    • Provide prior controller therapy history and escalation documentation as required.
    • Include specialist prescriber notes (pulmonologist or allergist/immunologist) and reauth evidence of positive clinical response.
    Documentation Required

    Opioid tolerance documentation

    For fentanyl oral transmucosal (breakthrough cancer pain), document the patient is taking a long‑acting opioid around the clock and has at least one week history demonstrating opioid tolerance at the specified minimum daily doses prior to approval.

    • Specify the long‑acting opioid regimen and duration of tolerance (≥1 week) with minimum daily dose documentation per policy thresholds.
    • Include pain or oncology specialist notes supporting use.
    Documentation Required

    HAE diagnostic documentation

    For icatibant acetate (HAE), submit diagnostic confirmation with C4 and C1‑INH testing or genetic testing/family history consistent with HAE‑nl‑C1INH; prescriber should be an immunologist or allergist for initial prescriptions.

    • Include C4 and C1‑INH antigenic/functional assay results or genetic testing.
    • Coverage duration: 12 months; reauth requires positive clinical response.
    Documentation Required

    Required diagnostic and growth documentation

    For growth‑related indications, include bone age criteria, growth measures (height SDS, percentiles), growth velocity, genetic testing where specified, and endocrinology consult notes; reauthorization should document expected adult height or treatment response.

    • Provide bone age assessment and growth velocity data per product thresholds.
    • Include endocrinologist consultation and prior therapy history when applicable.
    Documentation Required

    Molecular testing documentation

    For molecularly targeted therapies (e.g., Ibtrozi, Pemazyre, Retevmo, Piqray), provide FDA‑approved or CLIA‑certified test results confirming the required genomic alteration (ROS1, FGFR2/FGFR1, RET fusion/mutation, PIK3CA), plus prior treatment history and oncology specialist documentation.

    • Attach molecular testing reports from FDA‑approved or CLIA‑certified labs.
    • Include prior line therapy documentation and oncologist consult notes.
    Documentation Required

    Required laboratory monitoring

    Follow required laboratory monitoring documentation when mandated (e.g., Jynarque/Tolvaptan ALT/AST/bilirubin baseline and serial monitoring schedule; Kerendia baseline serum potassium, eGFR, and UACR), and submit test results and monitoring schedules with prior authorization requests.

    • Include baseline labs and planned monitoring frequency per product guidance.
    • Attach laboratory reports and specialty consult notes as applicable.
    Documentation Required

    Kesimpta — required medical information

    For Kesimpta initial requests include documentation of a relapsing form of MS and either trial and failure (minimum 4‑week supply), contraindication/intolerance to one DMT, or documentation that therapy is a continuation; prescriber must be a neurologist or document neurologist consultation for initial and reauthorization.

    • Do not submit concurrent DMT or other B‑cell targeted therapy use; such requests risk denial.
    • Reauthorization requires demonstration of positive clinical response to therapy.
    Documentation Required

    Kineret — required medical information

    For Kineret, include documentation of diagnosis (moderately to severely active RA or confirmed NOMID), required genetic or clinical confirmation for NOMID, prescriber specialty (rheumatologist, allergist/immunologist, or pediatrician as applicable), and evidence of clinical response for reauthorization.

    • For RA initial, document TF/C/I to two listed agents or attestation if trials are inappropriate.
    • Reauth requires documentation of positive clinical response; durations per product (initial often 6 months, reauth 12 months).
    Documentation Required

    Required diagnostic and prescriber documentation

    Provide medical records supporting diagnosis and prescriber specialty/consultation when required (e.g., CPP diagnostic criteria, advanced bone age, LH testing; endocrinology consults), and include required diagnostic details per product.

    • Attach relevant test results (e.g., peak LH after GnRHa testing) and specialist consultation notes.
    • Reauthorization must show positive clinical response as defined by the product.
    Documentation Required

    Genetic/molecular testing documentation

    Provide FDA‑ or CLIA‑approved genetic/molecular test results when indicated (e.g., BRAF V600E/V600K, H3 K27M) and detailed prior treatment history per product requirements.

    • Include laboratory or pathology reports confirming the required mutation.
    • Document prior therapy lines and reasons for discontinuation.
    Documentation Required

    Required clinical documentation

    Providers must submit diagnosis details, supporting test results (e.g., HRCT pattern, lung biopsy results, TTR mutation testing), and prior treatment history as specified for each product to support prior authorization decisions.

    • Include imaging reports, biopsy pathology, and genetic test results when required.
    • Provide specialist consultation notes and prior therapy documentation.
    Documentation Required

    Allergy testing and prior therapy documentation

    For Odactra, include positive specific IgE testing or skin testing and documentation of trial and failure, contraindication, or intolerance to an intranasal corticosteroid and an antihistamine before approval; prescriber should be an allergist/immunologist for initiation.

    • Attach positive IgE or skin test reports and records of prior intranasal corticosteroid and antihistamine trials.
    • Age requirement: 5–65 years for initial therapy.

    Formulary identifiers, codes, and clinical thresholds

    Formulary Identifiersmixed
    Formulary ID: 26218Formulary identifier used throughout document
    Drugs listed in this excerpt (no procedural codes provided)mixed
    No codes listed
    Formulary identifiermixed
    Formulary ID: 26218Formulary identifier and version referenced throughout these chunks
    Named drug productsmixed
    Dupixent INJ 200MG/1.14MLDupixent injection 200 mg/1.14 mL strength
    Dupixent 300MG/2MLDupixent injection 300 mg/2 mL strength
    Named drug productsmixed
    EmgalityEmgality (galcanezumab) injection — multiple strengths
    Named drug productsmixed
    EmpaveliEmpaveli (pegcetacoplan)
    Named drug productsmixed
    Pyrimethamine TABSPyrimethamine tablets
    Enbrel productsmixed
    Enbrel INJ 25MG/0.5MLProduct affected
    Enbrel 50MG/MLProduct affected
    Enbrel MiniProduct affected
    Enbrel SureclickProduct affected
    Evrysdi productsmixed
    EvrysdiSMA treatment (risdiplam) product affected
    Evrysdi SOLRProduct affected
    Other specialty biologicsmixed
    Fabrazymeα-galactosidase A enzyme for Fabry disease
    FasenraBenralizumab products listed
    Covered codes (none listed)mixed
    N/ANo specific CPT/HCPCS/ICD codes listed in this extract for Evrysdi
    Formulary identifiers and product listingsmixed
    Formulary ID: 26218Identifier used throughout these product entries
    Formulary identifiersmixed
    Formulary ID: 26218Formulary identifier (appears on multiple product entries)
    No explicit CPT/HCPCS/ICD-10/NDC codes in this segmentmixed
    No codes listed
    Product coverage entries (no billing codes provided)mixed
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes listed in these chunks; product names and clinical criteria are provided instead.
    Formulary identifiersmixed
    Formulary ID: 26218Formulary identifier shown on multiple product entries
    Formulary identifiers (document-level)mixed
    Formulary ID: 26218Formulary identifier for listed products and criteria (version 10)
    No procedure/diagnosis codes providedmixed
    N/ANo explicit CPT/HCPCS/ICD-10 codes listed in this excerpt
    Formulary identifiersmixed
    Formulary ID: 26218Formulary identifier and version for entries in this excerpt
    Atopic dermatitis clinical thresholds
    Atopic dermatitis BSA threshold>= 10% body surface area (BSA)
    Alternate severity measureSCORAD index >= 25
    Age requirement for initiationPatient is 12 years of age or older
    Plaque psoriasis clinical thresholds
    Plaque psoriasis BSA threshold>= 3% body surface area (BSA)
    Severe-location alternativeSevere scalp, palmoplantar, facial, or genital involvement qualifies regardless of %BSA
    Topical therapy prerequisiteTrial and failure of minimum 30-day supply of specified topical therapy (14 days for topical corticosteroids)
    CDAI threshold
    CDAI threshold> 220 (Crohn's Disease Activity Index)
    Other CD severity criteriaFrequent diarrhea and abdominal pain, >=10% weight loss, complications, or abnormal labs (eg, CRP)
    Context of useUsed to define moderately to severely active Crohn's disease for biologic initiation
    Migraine prevention (Aimovig/Emgality) thresholds
    Episodic migraine (EM) criterion>= 4 migraine days per month
    Chronic migraine (CM) criterion>= 8 migraine days per month
    Initial coverage durationInitial approval typically 6 months (reauth 12 months)
    EDSS and functional thresholds (dalfampridine)
    EDSS threshold for dalfampridineEDSS ≤ 7 (or not restricted to using a wheelchair if EDSS not measured)
    Required functional documentationPhysician confirmation of walking difficulty (eg, timed 25-foot walk)
    Prescriber requirementPrescribed by or in consultation with a neurologist for initial MS therapy
    Autoantibody thresholds for SLE
    ANA titer threshold (Benlysta)ANA titer >= 1:80
    Anti-dsDNA thresholdAnti-dsDNA >= 30 IU/mL
    Concomitant therapy requirementPatient must be receiving at least one standard-of-care treatment for active SLE
    anti-dsDNA and related SLE thresholds
    Anti-dsDNA thresholdAnti-dsDNA >= 30 IU/mL
    Supporting autoantibody requirementANA titer >= 1:80 may be used as corroborating autoantibody positivity
    Specialist involvementPrescribed by or in consultation with a rheumatologist (or nephrologist for lupus nephritis)
    Platelet count threshold (AdvSM)
    Platelet count threshold (AdvSM)> 50 x 10^9/L
    Indication contextApplies to advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM) entries
    Coverage durationCoverage listed as 12 months; approve continuation of prior therapy
    Cosentyx plaque psoriasis BSA threshold and prerequisites
    Plaque psoriasis threshold for Cosentyx>= 3% BSA OR severe scalp/palmoplantar/facial/genital involvement
    Topical therapy prerequisiteMinimum 4-week trial and failure of a topical therapy (eg corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor)
    Prescriber restrictionDermatologist involvement recommended for initial prescribing
    Cosentyx initial AS trial duration
    Ankylosing spondylitis initial trial durationMinimum 1-month trial and failure of an NSAID at maximally tolerated doses
    ContextRequired prior NSAID trial before Cosentyx initiation for AS
    PrescriberPrescribed by or in consultation with a rheumatologist for AS/nr-axSpA
    Onychomycosis terbinafine trial durations
    Terbinafine fingernail trial durationMinimum 6-week trial of oral terbinafine for fingernail onychomycosis
    Terbinafine toenail trial durationMinimum 12-week trial of oral terbinafine for toenail onychomycosis
    Diagnostic confirmation requirementOnychomycosis must be confirmed by KOH, culture, or histology and no lunula involvement

    Key definitions and clinical terms used in criteria

    TF/C/I (trial and failure / contraindication / intolerance)
    TF/C/I definitionTrial and failure, contraindication, or intolerance to specified conventional therapies
    Documentation neededProviders must document prior trial details, reason for failure/contraindication/intolerance, and duration at maximally tolerated doses
    Common applicationsUsed as prerequisite for biologic and specialty therapy initiation across inflammatory indications (eg, RA, PJIA, PsO, AS)
    CDAI — definition and threshold
    CDAI termCrohn's Disease Activity Index (CDAI)
    Severity threshold citedCDAI > 220 used to define moderately to severely active Crohn's disease
    Use in documentationSubmit CDAI or clinical features (diarrhea, weight loss, complications) to demonstrate disease activity
    MAC lung disease — definition and background therapy
    MAC lung disease definitionMycobacterium avium complex (MAC) lung disease treated as part of a combination antibacterial regimen
    Background therapy requirementUsed in patients who do not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of multidrug background regimen
    PrescriberPrescribed by or in consultation with infectious disease specialist or pulmonologist
    FGFR3 alteration — molecular testing requirement
    FGFR3 alteration testingFGFR3 susceptible genetic alterations must be detected by an FDA-approved or CLIA-approved test
    Required for coverageDocumentation of FGFR3 alteration is required for Balversa in urothelial carcinoma
    Test examplesTesting may be an FDA-cleared kit (eg, therascreen FGFR RGQ RT-PCR) or CLIA lab report
    Reauthorization — positive clinical response definition
    Reauthorization: positive clinical responseDefined by indication-specific improvement (eg, reduced BSA in psoriasis, reduced swollen/tender joint count in arthritis, mucosal healing or lab improvement for IBD)
    DocumentationProviders must submit objective measures comparing baseline to on-therapy status at reauth
    Variability by productDefinition and required measures vary by indication and are specified per product entry
    Eosinophilic esophagitis (EoE) histologic threshold
    EoE histology threshold>= 15 intraepithelial eosinophils per high power field (hpf)
    Clinical contextSymptomatic esophageal dysfunction with exclusion of other causes required along with histology
    Prior therapy requirementTrial and failure/intolerance to an 8-week PPI or topical esophageal corticosteroid required before some therapies
    Eosinophilic asthma phenotype — eosinophil thresholds
    Eosinophilic asthma baseline threshold>= 150 cells/µL peripheral blood eosinophils
    Higher threshold for COPD/type 2 inflammation>= 300 cells/µL (for COPD or some indications) within past 12 months
    Clinical requirementAnd history of exacerbations (eg >=2 systemic steroid courses or hospitalization in prior 12 months) for many biologic approvals
    Baseline motor assessments for SMA
    Baseline motor assessments (SMA)Standardized motor exams: HINE-2, HFMSE, RULM, CHOP-INTEND, MFM-32, or BSID-III Item 22 to document baseline function
    Genetic confirmation requirementSMN1 mutation/deletion and SMN2 copy number must be submitted for SMA therapies
    Prior gene therapy documentationIf prior gene therapy received, medical records must document inadequate response (eg sustained decrease in motor test over 6 months)
    Hereditary angioedema (HAE) — diagnostic confirmation
    HAE diagnostic confirmationDiagnosis confirmed by low C4 AND low C1-INH antigenic or functional level (Type I/II) OR by normal C4/C1-INH with supporting pathogenic gene mutation or family history
    Tests requiredC4 level and C1-INH antigenic or functional testing, or FDA/CLIA genetic test report
    PrescriberPrescribed by or in consultation with an immunologist or allergist for HAE prophylaxis/acute treatment
    Eosinophilic asthma — phenotype and documentation
    Eosinophilic asthma phenotype (alternate)>=150 cells/µL baseline and history of exacerbations or hospitalization in prior 12 months
    Age and controller therapy specificsAge-specific controller therapy requirements apply (eg medium/high-dose ICS +/- additional controllers) before biologic initiation
    PrescriberPrescribed by or in consultation with pulmonologist or allergist/immunologist
    Pediatric growth hormone deficiency (PGHD) diagnostic criteria
    PGHD diagnostic criteriaShort stature with height SDS <= -2.25 to -3.0 or low percentiles, delayed bone age and abnormal growth velocity as specified
    Required documentationBone age, height/weight percentiles, growth velocity, and endocrine evaluation; prescriber: endocrinologist
    ReauthorizationDemonstration of expected adult height trajectory or positive clinical response required for reauth
    IGF-1 deficiency (Increlex) criteria
    IGF-1 deficiency criteria (Increlex)Severe primary IGF-1 deficiency: height SDS <= -3.0 and basal IGF-1 SDS <= -3.0 with normal or elevated GH
    PrescriberPrescribed by or in consultation with an endocrinologist
    Coverage durationInitial and reauthorization periods listed as 12 months
    TF/C/I — abbreviated definition
    TF/C/I (abbreviated)Trial and failure, contraindication, or intolerance to specified conventional therapies — documented attempt and inadequate response or inability to use listed prior therapy
    Common useFrequently required before biologic/specialty agent initiation across RA, PJIA, PsO, AS, IBD
    Documentation noteProvider must supply duration, agent names, and reasons for failure/CI/intolerance
    PPFEV1 — definition and use
    PPFEV1 definitionPercent predicted forced expiratory volume in one second (ppFEV1) — objective lung function measure used for CF response evaluation
    Use in reauthorizationImprovement in ppFEV1 or decreased pulmonary exacerbations cited for reauth of CF therapies
    TestingBaseline and on-therapy spirometry recommended to document response
    NOMID — definition
    NOMID diagnostic criteriaNeonatal-Onset Multisystem Inflammatory Disease — confirmation by NLRP3 gene mutation OR specified clinical symptom set plus elevated acute phase reactants
    PrescriberPrescribed by or in consultation with appropriate specialist (eg rheumatology, immunology)
    ReauthReauthorization requires demonstration of clinical improvement

    Policy background and scope summary

    This coverage policy defines indication‑specific medical necessity criteria used to authorize specialty medications. For each product the document lists required diagnostic confirmation, applicable age and prescriber restrictions, prerequisite therapy trials where required, objective clinical thresholds when applicable, and a default coverage duration (commonly 12 months). Providers must submit prior authorization with documentation that meets the product‑specific criteria before benefits will be approved.

    Policy revision history

    2026-03-01effective_dateLatest

    Policy effective date (Formulary ID: 26218, Version 10) set to 03/01/2026.

    2026-02-02last_review

    Policy last updated / reviewed on 02/02/2026 (document metadata shows 'Last Updated: 02/02/2026').